Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

This is also called stage 4c bowel cancer. Surgery combined with chemotherapy is also called cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). It involves: the ...

After hours: January 7 at 6:53:22 PM EST Loading Chart for CRS ...

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of ...

Complete response (CR): patients who fully responded to treatment, meaning they no longer have signs or symptoms of cancer. Cytokine release syndrome (CRS): a condition that occurs when the body ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

"Leading Physician-Researcher: Advancing Medicine through Innovation and Discovery" "Independent researcher" ...

Jan. 3, 2025 — Tumor cells circulating in the blood are the 'germ cells' of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made ...